Deena A. Oren

Deena A. Oren

Auto-generated profile, based on publicly available information

Deena A. Oren

Structural Biology Resource Center, The Rockefeller University

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2021 in Science Translational Medicine
Verified
Journal Article
Open access
PDF file
ZWZijun Wang
Zijun Wang
JLJulio C. C. Lorenzi
Julio C. C. Lorenzi
FMFrauke Mücksch
Frauke Mücksch
SFShlomo Finkin
Shlomo Finkin
CVCharlotte Viant
Charlotte Viant
MNMichel C. Nussenzweig
Michel C. Nussenzweig
Human dimeric IgA antibodies are potent neutralizers of SARS-CoV-2.

9 September 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
ZWZijun Wang
Zijun Wang
JLJulio C. C. Lorenzi
Julio C. C. Lorenzi
FMFrauke Mücksch
Frauke Mücksch
SFShlomo Finkin
Shlomo Finkin
CVCharlotte Viant
Charlotte Viant
MNMichel C. Nussenzweig
Michel C. Nussenzweig
SARS-CoV-2 primarily infects cells at mucosal surfaces. Serum neutralizing antibody responses are variable and generally low in individuals that suffer mild forms of the illness. Although potent IgG antibodies can neutralize the virus, less is known about secretory antibodies such as IgA that might impact the initial viral spread and transmissibility from the mucosa. Here we characterize the IgA response to SARS-CoV-2 in a cohort of 149 individuals. IgA responses in plasma generally correlate with IgG responses and clones of IgM, IgG and IgA producing B cells that are derived from common progenitors are evident. Plasma IgA monomers are 2-fold less potent than IgG equivalents. However, IgA dimers, the primary form in the nasopharynx, are on average 15 times more potent than IgA monomers. Thus, secretory IgA responses may be particularly valuable for protection against SARS-CoV-2 and for vaccine efficacy.

18 May 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
AGAaron Gupta
Aaron Gupta
KKKevin S. Kao
Kevin S. Kao
RYRachel Yamin
Rachel Yamin
DODeena A. Oren
Deena A. Oren
YGYehuda Goldgur
Yehuda Goldgur
JRJeffrey V. Ravetch
Jeffrey V. Ravetch
Immunoglobulin G (IgG) antibodies contain a complex N-glycan embedded in the hydrophobic pocket between its heavy chain protomers. This glycan contributes to the structural organization of the Fc domain and determines its specificity for Fcγ receptors, thereby dictating distinct cellular responses. The variable construction of this glycan structure leads to highly-related, but non-equivalent glycoproteins known as glycoforms. We previously reported synthetic nanobodies that distinguish IgG glycoforms. Here, we present the structure of one such nanobody, X0, in complex with the Fc fragment of afucosylated IgG1. Upon binding, the elongated CDR3 loop of X0 undergoes a conformational shift to access the buried N-glycan and acts as a ‘glycan sensor’, forming hydrogen bonds with the afucosylated IgG N-glycan that would otherwise be sterically hindered by the presence of a core fucose residue. Based on this structure, we designed X0 fusion constructs that disrupt pathogenic afucosylated IgG1-FcγRIIIa interactions and rescue mice in a model of dengue virus infection.

30 March 2023 in Journal of Biological Chemistry
Verified
Journal Article
Open access
IKIlana B. Kotliar
Ilana B. Kotliar
ECEmilie Ceraudo
Emilie Ceraudo
KKKevin Kemelmakher-Liben
Kevin Kemelmakher-Liben
DODeena A. Oren
Deena A. Oren
ELEmily Lorenzen
Emily Lorenzen
TSThomas Sakmar
Thomas Sakmar
Cholestatic itch is a severe and debilitating symptom in liver diseases with limited treatment options. The class A G protein-coupled receptor (GPCR) Mas-related GPCR subtype X4 (MRGPRX4) has been identified as a receptor for bile acids, which are potential cholestatic pruritogens. An increasing number of GPCRs have been shown to interact with receptor activity–modifying proteins (RAMPs), which can modulate different aspects of GPCR biology. Using a combination of multiplexed immunoassay and proximity ligation assay, we show that MRGPRX4 interacts with RAMPs. The interaction of MRGPRX4 with RAMP2, but not RAMP1 or 3, causes attenuation of basal and agonist-dependent signaling, which correlates with a decrease of MRGPRX4 cell surface expression as measured using a quantitative NanoBRET pulse-chase assay. Finally, we use AlphaFold Multimer to predict the structure of the MRGPRX4–RAMP2 complex. The discovery that RAMP2 regulates MRGPRX4 may have direct implications for future drug development for cholestatic itch.

13 July 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
JSJan Soroczynski
Jan Soroczynski
LALauren J. Anderson
Lauren J. Anderson
JYJoanna L. Yeung
Joanna L. Yeung
JRJustin M. Rendleman
Justin M. Rendleman
DODeena A. Oren
Deena A. Oren
VRViviana I. Risca
Viviana I. Risca
Tagmentation combines DNA fragmentation and sequencing adapter addition by leveraging the transposition activity of the bacterial cut-and-paste Tn5 transposase, to enable efficient sequencing library preparation. Here we present an open-source protocol for the generation of multi-purpose hyperactive Tn5 transposase, including its benchmarking in CUT&Tag, bulk and single-cell ATAC-seq. The OpenTn5 protocol yields multi-milligram quantities of pG-Tn5 E54K, L372P protein per liter of E. coli culture, sufficient for thousands of tagmentation reactions and the enzyme retains activity in storage for more than a year.

6 December 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
IKIlana B. Kotliar
Ilana B. Kotliar
ECEmilie Ceraudo
Emilie Ceraudo
KKKevin Kemelmakher-Liben
Kevin Kemelmakher-Liben
DODeena A. Oren
Deena A. Oren
ELEmily Lorenzen
Emily Lorenzen
TSThomas Sakmar
Thomas Sakmar
Cholestatic itch is a severe and debilitating symptom in liver diseases with limited treatment options. The class A G protein-coupled receptor (GPCR) Mas-related GPCR subtype X4 (MRGPRX4) has been identified as a receptor for bile acids, which are potential cholestatic pruritogens. An increasing number of GPCRs have been shown to interact with receptor activity-modifying proteins (RAMPs), which can modulate different aspects of GPCR biology. Using a combination of multiplexed immunoassay and proximity ligation assay we show that MRGPRX4 interacts with RAMPs. The interaction of MRGPRX4 with RAMP2, but not RAMP1 or 3, causes attenuation of basal and agonist-dependent signaling, which correlates with a decrease of MRGPRX4 cell surface expression as measured using a quantitative NanoBRET pulse-chase assay. Finally, we use AlphaFold Multimer to predict the structure of the MRGPRX4-RAMP2 complex. The discovery that RAMP2 regulates MRGPRX4 may have direct implications for future drug development for cholestatic itch.